TUESDAY, July 23, 2024 (HealthDay Information) — Many breast most cancers survivors with indications for genetic counseling and testing don’t obtain it, in keeping with a examine revealed on-line July 15 within the Journal of Medical Oncology.
Steven J. Katz, M.D., from the College of Michigan in Ann Arbor, and colleagues examined receipt of genetic testing and communication with family members about outcomes into survivorship after prognosis of breast most cancers. Evaluation included 1,412 girls (aged 20 to 79 years) recognized with early-stage breast most cancers in 2014 or 2015 who accomplished surveys roughly seven months and 6 years after prognosis.
The researchers discovered that 47.4 % had indications for genetic testing at any time (28.0 % at baseline and 19.4 % on the time of follow-up solely). Simply over seven in 10 with a baseline indication reported genetic testing (71.9 %), in comparison with 53.3 % with a sign at follow-up solely and 35.0 % with no indication. When controlling for age and scientific indications, there have been no vital racial or ethnic variations in receipt of testing or genetic counseling. Girls receiving genetic testing with a reported pathogenic variant (62 girls) had been more likely to have talked to most or all their first-degree grownup family members about genetic testing, in comparison with these with a variant of unknown significance (49 girls) or a unfavorable discovering (419 girls; 62.7 % versus 38.8 and 38.0 %, respectively).
“Our findings reinforce the necessity for novel approaches to genetic threat analysis and testing in observe to focus on prevention and early detection methods for his or her sufferers and their households,” senior creator Allison Kurian, M.D., from Stanford College in California, mentioned in a press release.
Two authors disclosed ties to the biotechnology and pharmaceutical industries.
Summary/Full Textual content (subscription or fee could also be required)
Copyright © 2024 HealthDay. All rights reserved.
